d-pep-P6

d-pep-P6 is a **D-enantiomeric peptide (D-peptide)** experimentally developed to induce the differentiation of human leukemia cells, specifically targeting **acute myeloid leukemia (AML)**. Identified using a peptide phage display platform, both the D- and L-chirality forms of the peptide (pep-P6) were found to effectively induce AML cell differentiation. d-pep-P6 functions by **directly activating the Toll-like receptor 2 (TLR-2) signaling pathway**, resulting in the differentiation of AML cells toward the monocyte/macrophage lineage. This is evidenced by an increase in markers such as **CD11b and CD14** and cytokines including **IL-6, IL-1β, and TNF-α**. In mouse xenograft models, d-pep-P6 administration reduced AML burden in a dose-dependent manner, supporting its therapeutic potential as a differentiation agent for leukemia. The peptide promotes morphological maturation of leukemia cells, loss of stem-cell characteristics (CD34 marker), and induction of cytokine production supportive of differentiation[1][3][5].

Other names

d-pep-P6d-pep-P-6d-pep-P 6pep-P6pep-P-6pep-P 6